FLT3/IRAK4 Inhibitor Crystal Forms for Stable AML Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FLT3 inhibitors for treating acute myeloid leukemia (AML) face challenges with drug resistance and toxicity, particularly due to target-dependent and non-target-dependent mutations, necessitating the development of more effective and selective inhibitors.
Innovation Solution
Development of crystal forms and salt forms of a five-membered-fused six-membered compound that exhibit inhibitory effects on FLT3 and/or IRAK4, targeting both kinases to potentially reduce drug resistance and improve patient prognosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If first-generation FLT3 inhibitors are used, then broad-spectrum kinase inhibition is achieved, but efficacy is poor and toxicity is significantly increased
Solution Approach 1:
The patent applies local quality by designing a compound with selective kinase inhibition capability. The dual-target compound specifically targets FLT3 and IRAK4 kinases with high selectivity, rather than broadly inhibiting multiple kinases. This selective inhibition improves efficacy by focusing on the most relevant targets while reducing off-target effects that cause toxicity.
Solution Approach 2:
The patent changes the inhibition parameters from broad-spectrum to selective dual-target inhibition. By optimizing the compound structure to specifically inhibit FLT3 and IRAK4 with appropriate IC50 values, the patent achieves improved efficacy while maintaining acceptable toxicity profile, resolving the contradiction between broad inhibition and effective treatment.
2Measurement precision
If second-generation FLT3 inhibitors are used, then selectivity and activity are improved, but off-target effects still occur
Solution Approach 1:
The patent merges the inhibition of two specific kinases (FLT3 and IRAK4) into a single dual-target compound. By combining these two targeted inhibition functions, the patent achieves high selectivity for the intended targets while minimizing off-target effects, as the compound is designed to specifically bind to these two kinases rather than broadly inhibiting multiple kinases.
Solution Approach 2:
The patent creates a multi-functional compound that simultaneously inhibits both FLT3 and IRAK4 kinases. This dual-target capability allows the compound to address multiple resistance mechanisms and signaling pathways through a single agent, improving selectivity and reducing off-target effects compared to single-target inhibitors.
3Ease of operation
If FLT3 inhibitors are used as monotherapy, then treatment simplicity is maintained, but disease relapses rapidly with drug resistance emerging
Solution Approach 1:
The dual-target compound provides multi-functionality by simultaneously inhibiting both FLT3 and IRAK4 kinases. This allows the compound to act as a monotherapy with simplified treatment administration while addressing multiple resistance mechanisms and signaling pathways, thereby improving prognosis without requiring complex combination regimens.
Solution Approach 2:
The patent merges the functions of two separate inhibitors (FLT3 and IRAK4) into a single dual-target compound. This enables monotherapy administration that combines the benefits of dual-target inhibition, preventing rapid relapse and drug resistance while maintaining treatment simplicity.
4Reliability
If combination therapy with signaling pathway inhibitors is used, then non-target drug resistance is reduced, but treatment complexity increases and effect is still limited
Solution Approach 1:
The patent merges the inhibition of two key kinases (FLT3 and IRAK4) into a single dual-target compound, eliminating the need for complex combination therapy regimens. This approach reduces non-target drug resistance by simultaneously blocking multiple resistance pathways while maintaining simple monotherapy administration, thereby reducing treatment complexity.
Solution Approach 2:
The dual-target compound provides universal inhibition of both FLT3 and IRAK4 signaling pathways through a single agent. This multi-functional approach effectively reduces non-target drug resistance mechanisms while avoiding the complexity of combining multiple separate inhibitors, achieving reliable treatment with simplified therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal and salt forms demonstrate inhibitory effects on FLT3 and/or IRAK4, offering potential clinical benefits in reducing drug resistance and improving treatment outcomes for AML patients.
Implementation Method 1
The crystal forms and salt forms of the compound of the present disclosure exhibit inhibitory effects on FLT3 and/or IRAK4
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed in the present invention are a crystal form and salt form of a five- and six-membered compound, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof. Specifically, disclosed in the present invention are a crystal form and salt form of a five-and-six-membered compound as shown in formula I, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof. The crystal form and salt form of the compound of the present invention have an inhibitory effect on FLT3 and/or IRAK4. The crystal form of the present invention has a high single melt point, is thermodynamically stable, and has high crystallinity. The crystal form of the present invention represents good physical and chemical stability under strong illumination, high temperature and high humidity conditions, and the crystal form has weak hygroscopicity.